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Pharmacokinetic Considerations. Pharma-
cokinetics is that area of pharmacology concerned 
with the absorption, distribution, metabolism, and 
elimination of drugs. The processes by which absorp-
tion, distribution, and elimination take place are 
referred to as unit processes. These occur in-
dependently and concurrently, and involve such ac-
tivities as absorption into the blood, elimination from 
the blood, distribution between the blood and tissue, 
inactivation in tissues, and finally, elimination from 
the blood. Drug handling by the body can be 
characterized by the rate for each step or, more often, 
the rate of all processes. Classification of observed 
kinetics for these rate processes includes first-order, 
zero-order, and capacity-limited kinetics. In the 
description of these processes, we will use total body 
elimination as the model, as this is the way most data 
are handled clinically (I). 
The rate of first-order or exponential drug 
elimination is proportionate solely to the amount of 
drug present. The half-life is constant regardless of 
the quantity present. Thus, if the dosage is doubled, 
the half-life will remain the same. 
* Presented by Dr. David at the 27th Annual Stoneburner 
Lecture Series, February 8, 1974, at the Medical College of 
Virginia, Richmond. 
MCV QUARTERLY 10(4): 205-207, 1974 
Zero-order kinetics is the term used to describe 
processes where rates are constant per unit time; the 
time required to rid the body of one-half the drug is 
prolonged by increasing the body load. It is implied 
that the rate process is limited, and the rate of 
elimination is fixed. 
Capacity-limited kinetics describe a situation of 
a rate process being variable and between the limiting 
situations of first and zero-order. As the number of 
drug molecules approximates the number of 
metabolic sites, for example, special mathematical 
processes must be employed to describe the 
responses. As drug levels rise, the rate approaches the 
zero-order rate (constant amount eliminated/ time) 
and as levels fall, first-order rates are approximated. 
If we consider the situation of drug overdose or 
intoxication, it may help to clarify these different 
kinetic patterns. If zero kinetics are operative as in 
alcohol, the patient will rid himself of the same 
number of milligrams each hour regardless of serum 
level. At high levels in the body, this constant amount 
is a very small percent of body load and the rate of 
decline of serum concentratiop is slow indeed. If first-
order kinetics attain, as with phenobarbital, the total 
body load in the intoxicated patient will decline to 
one-half in the same time as the amount in the patient 
with a therapeutic amount. The situation of satura-
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tion kinetics is an intermediate between the two. An 
understanding of these principles is important mainly 
for preventing intoxication, for efficient alteration of 
dosage, and for understanding individual variations. 
While the determination of rate constants is im-
portant, other parameters are of concern. Absorption 
parameters include both the rate of absorption and 
the bioavailability or percentage of the drug absorbed 
which reaches the active sites in the body. Distribu-
tion parameters include not only the rate of distribu-
tion but also the volume of distribution or extent to 
which the drug is found outside the blood; this is 
affected by protein binding. Protein binding may be 
affected by disease states and other drugs. 
The pharmacologic effect on the desired organ 
or organ system will be dependent upon the amount 
of time in the body, the time exposed to the target 
organ, and the specific properties of the drug used. 
The occurrence of side effects is dependent upon 
similar considerations. 
There are many patient variables such as in-
dividual physiology, pathology, and genetic 
characteristics, as well as developmental and en-
vironmental factors which effect drug response. A 
drug serum assay (drug level determination) is but a 
small part of the data necessary to make an intelligent 
judgment with regard to maximizing the desired 
effect in therapy. Serum assay determines only the 
quantity in the serum and basic assumptions must be 
made in regard to the organ or organ system where 
the drug is adive. Many factors affect the 
relationship between serum concentration and drug 
effect. An understanding of pharmacokinetic prin-
ciples will result in less trial-and-error phar-
macotherapy and more frequent consideration of im-
portant variables. For example, if the physician, as 
his goal in treating the seizure patient, has established 
that a patient should have no subsequent seizures, 
then he will, with a basic understanding, be able to 
prevent some of the seizures which occur during the 
start-up and dosage-adjustment phases of drug 
therapy; he may also avoid intoxication. 
Clinical Considerations. The availability of drug 
assays and pharmacokinetic data has already pro-
vided some useful information for the clinician (2). 
This has increased our knowledge in four areas: 
the initiation of therapy, dosage regimens, routes 
of administration, and adjustment of dosage for 
the four basic anticonvulsants-phenobarbital, 
diphenylhydantoin (Dilantin®), primidone (Myso-
line®), and ethosuximide (Zarontin®). These are 
the most commonly used agents, and there are, 
consequently, more pharmacokinetic data regarding 
them. 
Initiation of Therapy. With respect to the ini-
tiation of dosage, there is a rule of thumb that can be 
helpful: If a maintenance dosage regimen is used to 
initiate therapy, four times the half-life of the agent 
will be required to achieve 90% of the ultimate serum 
plateau. Since such a long time is required to reach 
this plateau with some drugs, such as diphenylhydan-
toin, loading has been used, particularly to achieve 
rapid therapeutic levels . Phenobarbital and 
primidone, however, produce significant drowsiness, 
so they are usually not "loaded." With ethosuxi-
mide, employed in the treatment of absence seizures, 
loading doses are usually not used because of the 
mild nature of the seizure being treated. Agents with 
long half-lives, however, are, potentia lly, those with 
which the initial dose should be larger than the 
maintenance dose. 
The usual starting dose for phenobarbital is 5 
mg/ kg/ day in the child and about I mg/ kg/ day in 
the adult. The half-life is 18-70 hours in a child (3) 
and 55-120 hours in the adult (4). In general, the 
younger the individual, the shorter the half-life. 
The starting dose for diphenylhydantoin is 5-8 
mg/ kg/ day for the child and 4-6 mg/ kg/ day for the 
adult. Once the therapeutic level is achieved, the ap-
parent half-life is 8-12 hours. Loading of 
diphenylhydantoin can be accomplished by giving 
three times the maintenance dose in three divided 
doses, three hours apart on the first day (5); the 
second day, the usual maintenance dose is given. 
Therapeutic levels are reached in 12 hours, and peak 
serum levels are usually achieved on the third day. 
Diphenylhydantoin may also be loaded intravenously 
with accompanying electrocardiographic monitoring, 
but not more than 50 mg/ minute should be given (6). 
The initial dose ofprimidone administered is less 
than the maintenance level because of the initial po-
tent hypnotic side effects. Usually, a maintenance 
dose of 20 mg/ kg/ day is sought. Switching a patient 
from phenobarbital to full maintenance primidone 
usually can be accomplished without producing 
sedative side effects. The half-life of primidone is 
short-3-12 hours (7). 
The starting dose of ethosuximide is 20 mg/ kg/ 
day. The half-life is a mean of 66 hours in an ad ult 
and 30 hours in a child. 
Dosage Regimens. Because phenobarbital and 
ethosuximide have long half-lives, once-daily ad-
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ministration can be employed, and because of 
diphenylhydantoin's slow absorption, it also can be 
given once daily. Primidone, having a relatively short 
half-life, generally, should be given three times a day, 
although some patients are well treated with twice-
daily dosage. Ethosuximide may have a gastric irri-
tant effect, so some clinicians employ it in a twice-
daily regimen. 
Routes of Administration. Ethosuximide and 
primidone can be given only orally. Phenobarbital 
can be given orally, intramuscularly or intravenously. 
While diphenylhydantoin can be given orally or in-
travenously, intramuscular administration usually 
fails to release sufficient diphenylhydantoin to the 
blood, when given as the usual maintenance dose. 
Doubling the maintenance dose when giving it in-
tramuscularly is satisfactory, particularly when using 
this route for short-term replacement of oral therapy, 
as in surgery (8) . 
Adjustment of Dose. In adjusting the level of 
medication, one should remember that phenobarbital 
and ethosuximide are eliminated by first-order 
kinetics and diphenylhydantoin, by capacity-limited 
kinetics (9). Consequently, doubling the dose of 
phenobarbital will double the blood level, as trebling 
the dose will triple the blood level. When levels of 
diphenylhydantoin are low, a similar relationship ex-
ists. At higher levels, in practice, apparently, above 10 
µg/ m1, the effect of capacity-limited kinetics is that 
apparently relatively small dosage increments result in 
greater serum level increases than is expected or 
desired. Half increments are probably in order here. 
The therapeutic ranges given for phenobarbital levels 
are 10-50 µg / ml, for primidone are 5-20 µg / ml, and 
for ethosuximide are 40-80 µg/ml. The therapeutic 
range for diphenylhydantoin is 6-20 µg / ml. Recent 
work indicates that low serum levels are effective in 
controlling seizures particularly in children. 
Compliance. While our knowledge of phar-
macokinetics has increased, one larger problem ex.ists 
in the area of compliance. Compliance is poor when 
administration of the drug is too frequent, when mul-
tiple drugs are used on a different schedule, and when 
the dosage form is unacceptable. 
Three of the anticonvulsants mentioned can be 
given as infrequently as once a day. This eliminates 
the necessity for children to take these agents in 
school. When multiple agents are given, it is relatively 
easy to give all medications at one time. 
Phenobarbital is available as an elixir, diphenyl-
hydantoin and primidone, as suspensions. Where it is 
possible, the tablet form assures a more reliable 
dosage intake. In the young child, all can be crushed 
and given with jelly or other vehicles. Di-
phenylhydantoin comes as a chewable tablet, and 
while it may produce more gingival hypertrophy than 
the capsule, we continue to use it extensively. 
Ethosuximide constitutes a rather special problem 
being a liquid within a rather large gelatin capsule. 
The capsule can be pricked by a pin and the liquid 
mixed with juice or another vehicle by the pharmacist 
or mother. One ingenious mother related that the 
capsule can be frozen, then cut in half and given with 
ice cream. 
Memory crutches are useful. The most inexpen-
sive is the traditional egg carton. Dial-a-packs are 
also available and can be loaded by the patient with 
his drug or drugs. 
A new era is here. Practical pharmacokinetics, 
skillfully utilized by the clinician, should aid im-
measurably in producing seizure-free patients and in 
reaching the goal quickly with fewer side effects. 
REFERENCES 
1. JUSKO WJ: Pharmacokinetic principles in pediatric phar-
macology. Pediat C/in N Am 19:8 l, 1972. 
2. GARRETTSON LK: Pharmacology of anticonvulsants. Pediat 
C/in N Am 19: l 79, l 972. 
3. HEINZE E, KAMPFFMEYER HG: Biological half-life of phenobar-
bital in human babies. Klin Wschr 49: 1146, 1971. 
4. LONS P: Plasma levels and urinary excretion of three barbituric 
acids after oral administration to man. Acta Pharmaco/ Toxico/ 
10: 147, l 956. 
5. WILDER BJ, SERRANO EE, RAMSEY RE: Plasma diphenylhydan-
toin levels after loading and maintenance doses. Clin Pharmaco/ 
Therap 14:797, l 973. 
6. Kun H, McDOWELL F: Management of epilepsy with 
diphenylhydantoin sodium. JAMA 203:969, 1968. 
7. GALLAGHER BB, BAUMEL IP: Primidone: Absorption, distribu-
tion, and excretion. In: Antiepileptic Drugs. Eds. Woodbury 
OM, Penry JK, and Schmidt, New York, Raven Press, 1972, p. 
357. 
8. SERRANO EE, ROYE DB, HAMMER RH, WILDER BJ: Plasma 
diphenylhydantoin values after oral and intramuscular ad-
ministration of diphenylhydantoin. Neurology 23:3 1 l , 1973. 
9. HOLCOMB R, LYNN R, HARVEY BJ, SWEETMAN BJ, GERBER N: 
Intoxication with 5,5-diphenylhydantoin (Dilantin®). J Pediat 
80:627, 1972. 
